Magnetically Activated Piezoelectric 3D Platform Based on Poly(Vinylidene) Fluoride Microspheres for Osteogenic Differentiation of Mesenchymal Stem Cells

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Guillot-Ferriols, Maria
- Inmaculada Garcia-Briega, Maria
- Costa, Carlos M.
- Lanceros-Mendez, Senentxu
Grupos
Abstract
Mesenchymal stem cells (MSCs) osteogenic commitment before injection enhances bone regeneration therapy results. Piezoelectric stimulation may be an effective cue to promote MSCs pre-differentiation, and poly(vinylidene) fluoride (PVDF) cell culture supports, when combined with CoFe2O4 (CFO), offer a wireless in vitro stimulation strategy. Under an external magnetic field, CFO shift and magnetostriction deform the polymer matrix varying the polymer surface charge due to the piezoelectric effect. To test the effect of piezoelectric stimulation on MSCs, our approach is based on a gelatin hydrogel with embedded MSCs and PVDF-CFO electroactive microspheres. Microspheres were produced by electrospray technique, favouring CFO incorporation, crystallisation in beta-phase (85%) and a crystallinity degree of around 55%. The absence of cytotoxicity of the 3D construct was confirmed 24 h after cell encapsulation. Cells were viable, evenly distributed in the hydrogel matrix and surrounded by microspheres, allowing local stimulation. Hydrogels were stimulated using a magnetic bioreactor, and no significant changes were observed in MSCs proliferation in the short or long term. Nevertheless, piezoelectric stimulation upregulated RUNX2 expression after 7 days, indicating the activation of the osteogenic differentiation pathway. These results open the door for optimising a stimulation protocol allowing the application of the magnetically activated 3D electroactive cell culture support for MSCs pre-differentiation before transplantation.
Datos de la publicación
- ISSN/ISSNe:
- 2310-2861, 2310-2861
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/gels8100680
- Factor de Impacto:
- 0,693 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
GELS MDPI
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- mesenchymal stem cells; osteoblastogenesis; piezoelectricity; poly(vinylidene) fluoride; hydrogel
Proyectos asociados
RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010
MECANISMOS TRANSCRIPCIONALES IMPLICADOS EN EL HIGADO GRASO NO ALCOHOLICO DE ORIGEN METABOLICO E IATROGENICO: INFLUENCIA DE LA RESISTENCIA A LA INSULINA
Investigador Principal: RAMIRO JOVER ATIENZA
PI10/00194 . INSTITUTO DE SALUD CARLOS III . 2010
METABONOMICA Y CITOMICA COMO NUEVOS PARADIGMAS Y ESTRATEGIAS EXPERIMENTALES PARA EL ESTUDIO DE LOS MECANISMOS DE HEPATOTOXICIDAD DE FARMACOS, PREDICCION DE SU POTENCIAL HEPATOTOXICO Y LA TRANSICION DE HEPATITIS I ATROGENICA A AUTOINMUNE.
Investigador Principal: MARÍA TERESA DONATO MARTÍN
PI10/00923 . INSTITUTO DE SALUD CARLOS III . 2010
APROXIMACIONES METABONÓMICAS PARA EL ESTUDIO DE LA HEPATOTOXICIDAD IDIOSINCRÁSICA CON BASE METABÓLICA Y LA IDENTIFICACIÓN DEL AGENTE CAUSAL.
Investigador Principal: MARÍA TERESA DONATO MARTÍN
PI13/00986 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
MÉDULA ÓSEA ARTIFICIAL PARA PERSONALIZAR EL TRATAMIENTO DE PACIENTES DE CÁNCERES DE SANGRE-TISSUE MIELOMA.
Investigador Principal: JOSE LUIS GOMEZ RIBELLES
2015_0800_CPC_GOMEZ . CONSELLERIA DE EDUCACION . 2016
EUTOXRISK21. AN INTEGRATED EUROPEAN ‘FLAGSHIP’ PROGRAM DRIVING MECHANISM-BASED.
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
681002_EUTOXRISK_CASTELL_H2020-PHC-33-2015 . COMISION EUROPEA . 2016
Tu hospital investiga RRI.
Investigador Principal: ANA ISABEL JUAN ROCH
FCT-18-14018 . FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA . 2019
IMPROVING FEASIBILITY OF LIVER CELL THERAPY: NEW CELL SOURCES AND STRATEGIES TO IMPROVE THE CLINICAL OUTCOME. (PROYECTO)
Investigador Principal: LAIA TOLOSA PARDO
CP16/00097 . INSTITUTO DE SALUD CARLOS III . 2017
ESTANCIA DE PERSONAL INVESTIGADOR DOCTOR EN CENTROS DE INVESTIGACION RADICADOS FUERA DE LA COMUNIDAD VALENCIANA. Laia Tolosa Pardo
Investigador Principal: LAIA TOLOSA PARDO
BEST2020/144 . CONSELLERIA DE EDUCACION . 2020
Nuevas tecnologías traslacionales para el tratamiento de enfermedades hepáticas: preacondicionamiento del hígado, nuevas fuentes celulares y biomateriales en terapia celular.
Investigador Principal: LAIA TOLOSA PARDO
PI21/00223 . INSTITUTO DE SALUD CARLOS III . 2022
Characterisation of human variability in Toxicodynamics: towards the development of quantitative Adverse Outcome Pathways (qAOPs).
Investigador Principal: LAIA TOLOSA PARDO
OC/EFSA/SCER/2021/03 . EUROPEAN FOOD SAFETY AUTHORITY . 2021
Cita
Guillot M,Inmaculada Garcia M,Tolosa L,Costa CM,Lanceros S,Gomez JL,Gallego G. Magnetically Activated Piezoelectric 3D Platform Based on Poly(Vinylidene) Fluoride Microspheres for Osteogenic Differentiation of Mesenchymal Stem Cells. Gels. 2022. 8. (10):680. IF:4,600. (1).